Perspective Therapeutics, Inc. — Earnings
Most recent reported period: FY2023 (Q3) (filed for period ending 2023-09-30) · sourced from SEC EDGAR
Next earnings (estimated): Sat, December 30, 2023 — 853 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | — | — | — | — | — |
| 2025-09-30 | — | — | $-26M | ↓-71.7% | — |
| 2025-06-30 | — | — | $-21M | ↓-83.6% | — |
| 2025-03-31 | — | — | $-18M | ↓-48.0% | — |
| 2024-12-31 | — | — | — | — | — |
| 2024-09-30 | — | — | $-15M | ↓-46.0% | — |
| 2024-06-30 | — | — | $-12M | ↓-5.4% | — |
| 2024-03-31 | — | — | $-12M | ↓-3211.1% | — |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2023 (Q3)
Revenue
$2M
↑+27.3% +$468K YoY
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 61 quarters
margin trajectory tells the operating-leverage storyGross Margin↑+9.7pts
33.8%
Operating Margin↓-201.1pts
-446.2%
Net Margin↓-237.0pts
-474.0%
Go deeper
CATX Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyCATX Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics